Charles Zhou
Stock Analyst at Guggenheim
(2.70)
# 2,112
Out of 5,063 analysts
11
Total ratings
62.5%
Success rate
18.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences | Maintains: Buy | $17 → $20 | $34.70 | -42.36% | 2 | Aug 25, 2025 | |
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $153.79 | -11.57% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $23.82 | -32.83% | 1 | Mar 8, 2023 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.37 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.31 | +4,174.81% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $2.10 | +2,090.48% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $4.56 | - | 2 | Jan 22, 2020 |
Cogent Biosciences
Aug 25, 2025
Maintains: Buy
Price Target: $17 → $20
Current: $34.70
Upside: -42.36%
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $153.79
Upside: -11.57%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $23.82
Upside: -32.83%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.37
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.31
Upside: +4,174.81%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $2.10
Upside: +2,090.48%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.56
Upside: -